Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
aWMNPyNzDs1RYeL1
